, /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a aesculapian instrumentality institution focused connected commercializing the world's lone successful vivo Intravaginal Culture System (IVC), INVOcell®, an effectual and affordable attraction for patients diagnosed with infertility, contiguous announced the institution volition grounds astatine the 2022 Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) being held October 22-26, 2022 successful Anaheim, California astatine booth #1312.
In attendance from INVO Bioscience volition beryllium Steve Shum, CEO; Mike Campbell, COO and VP, Business Development; Chris Myer, Senior VP, Business Development, Americas; Inger Britt Carlsson, PhD, VP, Global Medical Affairs; and Bojan (Bo) Mitrovic, PhD, Director, Sales, US.
The ASRM Scientific Congress & Expo is an in-person league held each October successful assorted cities crossed the U.S. The Society is dedicated to the advancement of the subject and signifier of reproductive medicine. It accomplishes its ngo done the pursuit of excellence successful evidence-based, life-long acquisition and learning, done the advancement and enactment of innovative research, done the improvement and dissemination of the highest ethical and prime standards successful diligent care, and done advocacy connected behalf of physicians and affiliated healthcare providers and their patients.
This year's Congress features tracks for Reproductive Endocrinology, Assisted Reproductive Technology, ART Lab, Reproductive Surgery, Mental Health, Nursing, Genetic Counseling, Male Reproduction, and more.
Steve Shum, CEO of INVO Bioscience, commented, "We look guardant to further showcasing our innovative INVOcell solution, the world's archetypal intravaginal civilization method for the incubation of oocytes and sperm during fertilization and aboriginal embryo development, arsenic good arsenic highlighting our caller commercialized advancement to the reproductive assemblage astatine the 2022 ASRM Congress & Expo. INVO's ngo to instrumentality caller aesculapian technologies aimed astatine expanding the availability of affordable, high-quality, patient-centered fertility attraction is ideally aligned with the goals and objectives of ASMR. We look guardant to different tremendous lawsuit this year."
About INVO Bioscience®
We are a commercial-stage fertility institution dedicated to expanding the assisted reproductive exertion ("ART") marketplace by making fertility attraction accessible and inclusive to radical astir the world. Our superior ngo is to instrumentality caller aesculapian technologies aimed astatine expanding the availability of affordable, high-quality, patient-centered fertility care. Our flagship merchandise is INVOcell®, a revolutionary aesculapian instrumentality that allows fertilization and aboriginal embryo improvement to instrumentality spot successful vivo wrong the woman's body. This attraction solution is the world's archetypal intravaginal civilization method for the incubation of oocytes and sperm during fertilization and aboriginal embryo development. This technique, designated arsenic "IVC", provides patients a much natural, intimate, and much affordable acquisition successful examination to different ART treatments. We judge the IVC process tin present comparable results astatine a fraction of the outgo of accepted successful vitro fertilization ("IVF") and is simply a importantly much effectual attraction than intrauterine insemination ("IUI"). Our commercialization strategy is focused connected the opening of dedicated "INVO Centers" offering the INVOcell ® and IVC process (with 3 centers successful North America present operational), successful summation to continuing to administer and merchantability our exertion solution into existing fertility clinics. For much information, delight sojourn www.invobio.com.
Safe Harbor Statement
This merchandise includes forward-looking statements wrong the meaning of Section 27A of the Securities Act of 1933, arsenic amended, and Section 21E of the Securities Exchange Act of 1934, arsenic amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected aboriginal fiscal position, results of operations, currency flows, financing plans, concern strategies, products and services, competitory positions, maturation opportunities, plans and objectives of absorption for aboriginal operations, arsenic good arsenic statements that see words specified arsenic "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and different akin expressions are forward-looking statements. All forward-looking statements impact risks, uncertainties and contingencies, galore of which are beyond our control, which whitethorn origin existent results, performance, oregon achievements to disagree materially from anticipated results, performance, oregon achievements. Factors that whitethorn origin existent results to disagree materially from those successful the forward-looking statements see those acceptable distant successful our filings astatine www.sec.gov. We are nether nary work to (and expressly disclaim immoderate specified work to) update oregon change our forward-looking statements, whether arsenic a effect of caller information, aboriginal events oregon otherwise.
SOURCE INVO Bioscience, Inc.
English (US)